Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

5 Jul 2019

Abstract excerpt

BACKGROUND: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim of this study was to identify novel epigenetic biomarkers associated to trastuzumab resistance in HER2+ BC patients. METHODS: We performed a genome-wide DNA methylation (450K...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Protease and Inhibitor Mechanisms
Share to TGF-β signaling in diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31277676
DOI: 10.1186/s13058-019-1160-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancerPMID 31277676Read ↗

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast CancerSemantic proximity Read ↗

Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancerSemantic proximity Read ↗

Investigation of ITGB3 Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast CancerSemantic proximity Read ↗

LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.Semantic proximity Read ↗

Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancerSemantic proximity Read ↗

mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer.Semantic proximity Read ↗

Identification of markers to predict benefit from trastuzumab treatmentSemantic proximity Read ↗

Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast CancerSemantic proximity Read ↗

RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cellsSemantic proximity Read ↗

TROP2 methylation and expression in tamoxifen-resistant breast cancerSemantic proximity Read ↗

Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted TherapySemantic proximity Read ↗

ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.